Carlo Heirman mainly investigates Antigen, Dendritic cell, Cytotoxic T cell, Immunology and Antigen presentation. His Antigen study combines topics from a wide range of disciplines, such as Cancer research, Immune system, CD40 and Cancer immunotherapy. Carlo Heirman interconnects T cell and Cell biology in the investigation of issues within Dendritic cell.
He is interested in Antigen-presenting cell, which is a field of Cytotoxic T cell. His biological study spans a wide range of topics, including Interleukin 12 and Melanoma. His Antigen presentation research incorporates themes from Epitope, Molecular biology and Electroporation.
Carlo Heirman mainly focuses on Immunology, Antigen, Immunotherapy, Dendritic cell and Cytotoxic T cell. His research integrates issues of Cancer research, Electroporation, Antigen presentation and Cancer immunotherapy in his study of Antigen. His study on Dendritic cell is mostly dedicated to connecting different topics, such as Cell biology.
In his work, RNA and Bioinformatics is strongly intertwined with Messenger RNA, which is a subfield of Cell biology. His Cytotoxic T cell research incorporates elements of Molecular biology, Cytokine secretion and Interferon. His CD8 study combines topics in areas such as Epitope, T cell, Priming and Virology.
His scientific interests lie mostly in Cancer research, Immunotherapy, Immune system, Immunology and Messenger RNA. His study in Immunotherapy is interdisciplinary in nature, drawing from both Dendritic cell, Antigen and Transfection. His Antigen study combines topics from a wide range of disciplines, such as Virus and Adjuvant.
His work carried out in the field of Immune system brings together such families of science as Immunogen and Vaccination. His Immunology research includes elements of Cytotoxic T cell, Transplantation and Virology. His Messenger RNA research incorporates themes from RNA, Melanoma, Electroporation and Cell biology.
His primary areas of investigation include Immunology, Immunotherapy, Dendritic cell, Cytotoxic T cell and T cell. His research on Immunology often connects related topics like Pharmacology. His Dendritic cell research is multidisciplinary, incorporating perspectives in Messenger RNA and Immunity.
His studies in Antigen-presenting cell and Antigen presentation are all subfields of Cytotoxic T cell research. His T cell research is multidisciplinary, incorporating elements of CD8, Antigen, CD40 and Cell biology. His studies deal with areas such as Interferon and Cancer research as well as Antigen.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo.
Roberto Maldonado-López;Thibaut De Smedt;Patrick Michel;Jacques Godfroid.
Journal of Experimental Medicine (1999)
Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation
M. H. C. Bakkus;C. Heirman;I. Van Riet;B. Van Camp.
CD83 expression on dendritic cells and T cells: correlation with effective immune responses.
Cindy Aerts-Toegaert;Carlo Heirman;Sandra Tuyaerts;Jurgen Corthals.
European Journal of Immunology (2007)
Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients
Aude Bonehill;An M.T. Van Nuffel;Jurgen Corthals;Sandra Tuyaerts.
Clinical Cancer Research (2009)
Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules.
Aude Bonehill;Carlo Heirman;Sandra Tuyaerts;Annelies Michiels.
Journal of Immunology (2004)
Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma
Sofie Wilgenhof;Jurgen Corthals;Carlo Heirman;Nicolas van Baren.
Journal of Clinical Oncology (2016)
Enhancing the T-cell Stimulatory Capacity of Human Dendritic Cells by Co-electroporation With CD40L, CD70 and Constitutively Active TLR4 Encoding mRNA
Aude Bonehill;Sandra Tuyaerts;An M T Van Nuffel;Carlo Heirman.
Molecular Therapy (2008)
Role of CD8alpha+ and CD8alpha- dendritic cells in the induction of primary immune responses in vivo.
R Maldonado-López;T De Smedt;B Pajak;C Heirman.
Journal of Leukocyte Biology (1999)
Current approaches in dendritic cell generation and future implications for cancer immunotherapy.
Sandra Tuyaerts;Joeri L. Aerts;Jurgen Corthals;Bart Neyns.
Cancer Immunology, Immunotherapy (2007)
A MAGE-A3 Peptide Presented by HLA-DP4 Is Recognized on Tumor Cells by CD4+ Cytolytic T Lymphocytes
Erwin S Schultz;Bernard Lethé;Cesar L Cambiaso;Jacques Van Snick.
Cancer Research (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: